SG/CALL/AMGEN/380/0.1/20.12.24 Stock

DE000SU6VRY0

Market Closed - Boerse Frankfurt Warrants 03:37:02 2024-05-31 pm EDT
0.53 ^EUR	+6.00%

1 month	+120.83%
3 months	+89.29%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Latest news about AMGEN INC.

Amgen : 2024 Annual Meeting of Stockholders Presentation	May. 31	PU
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	May. 28	RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	May. 28	DJ
Weight-loss drug forecasts jump to $150 billion as supply grows	May. 28	RE

More news

Quotes 5-day view

Date	Price	Change
24-05-31	0.53	+6.00%
24-05-30	0.5	+16.28%
24-05-29	0.43	-12.24%
24-05-28	0.49	-15.52%
24-05-27	0.58	+1.75%

Real-time Boerse Frankfurt Warrants

Last update May 31, 2024 at 03:37 pm EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	Société Générale
WKN	SU6VRY
ISIN	DE000SU6VRY0
Date issued	2024-01-10
Strike	380 $
Maturity	2024-12-20 (202 Days)
Parity	10 : 1
Emission price	0.93 €
Emission volume	N/A
Settlement	Barausgleich
Currency	EUR

Technical Indicators

Highest since issue	1.32 €
Lowest since issue	0.17 €
Spread	0.02 €
Spread %	3.51%

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company